New Risk • Mar 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 16% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$1.9m free cash flow). Earnings have declined by 42% per year over the past 5 years. Revenue is less than US$1m (NZ$1.0m revenue, or US$599k). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Market cap is less than US$100m (AU$27.2m market cap, or US$18.7m). Reported Earnings • Feb 25
First half 2026 earnings released: NZ$0.003 loss per share (vs NZ$0.004 loss in 1H 2025) First half 2026 results: NZ$0.003 loss per share (improved from NZ$0.004 loss in 1H 2025). Revenue: NZ$507.6k (down 29% from 1H 2025). Net loss: NZ$1.24m (loss narrowed 6.5% from 1H 2025). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. New Risk • Feb 25
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NZ$1.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$1.9m free cash flow). Earnings have declined by 42% per year over the past 5 years. Revenue is less than US$1m (NZ$1.0m revenue, or US$625k). Minor Risk Market cap is less than US$100m (AU$21.5m market cap, or US$15.2m). Announcement • Oct 20
Zoono Group Limited, Annual General Meeting, Nov 20, 2025 Zoono Group Limited, Annual General Meeting, Nov 20, 2025. Location: hall chadwick, level 40, 2 park street, sydney nsw 2000 Australia New Risk • Oct 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 17% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 59% per year over the past 5 years. Revenue is less than US$1m (NZ$1.3m revenue, or US$716k). Minor Risks Share price has been volatile over the past 3 months (17% average weekly change). Market cap is less than US$100m (AU$20.3m market cap, or US$13.1m). Reported Earnings • Aug 29
Full year 2025 earnings released: NZ$0.011 loss per share (vs NZ$0.041 loss in FY 2024) Full year 2025 results: NZ$0.011 loss per share (improved from NZ$0.041 loss in FY 2024). Revenue: NZ$1.25m (up 19% from FY 2024). Net loss: NZ$3.93m (loss narrowed 57% from FY 2024). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Announcement • Aug 28
Zoono Group Limited has completed a Follow-on Equity Offering in the amount of AUD 1.777229 million. Zoono Group Limited has completed a Follow-on Equity Offering in the amount of AUD 1.777229 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 22,428,730
Price\Range: AUD 0.035
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 28,349,219
Price\Range: AUD 0.035
Transaction Features: Rights Offering Announcement • Jun 21
Zoono Group Limited has filed a Follow-on Equity Offering in the amount of AUD 1.777169 million. Zoono Group Limited has filed a Follow-on Equity Offering in the amount of AUD 1.777169 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 50,776,259
Price\Range: AUD 0.035
Transaction Features: Rights Offering New Risk • May 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$2.7m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 57% per year over the past 5 years. Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Revenue is less than US$1m (NZ$1.1m revenue, or US$659k). Market cap is less than US$10m (AU$12.1m market cap, or US$7.77m). New Risk • Feb 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$3.2m free cash flow). Earnings have declined by 47% per year over the past 5 years. Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Revenue is less than US$1m (NZ$1.0m revenue, or US$596k). Market cap is less than US$10m (AU$9.95m market cap, or US$6.26m). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change). Announcement • Oct 11
Zoono Group Limited, Annual General Meeting, Nov 13, 2024 Zoono Group Limited, Annual General Meeting, Nov 13, 2024. Location: hall chadwick, level 40, 2 park street, sydney nsw 2000, Australia Reported Earnings • Aug 22
Full year 2024 earnings released: NZ$0.041 loss per share (vs NZ$0.002 loss in FY 2023) Full year 2024 results: NZ$0.041 loss per share (further deteriorated from NZ$0.002 loss in FY 2023). Revenue: NZ$1.05m (down 69% from FY 2023). Net loss: NZ$9.09m (loss widened NZ$8.74m from FY 2023). New Risk • May 28
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 99% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Earnings have declined by 32% per year over the past 5 years. Shareholders have been substantially diluted in the past year (99% increase in shares outstanding). Market cap is less than US$10m (AU$9.69m market cap, or US$6.46m). Minor Risk Revenue is less than US$5m (NZ$2.1m revenue, or US$1.3m). Announcement • May 18
Zoono Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.366507 million. Zoono Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.366507 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 13,574,320
Price\Range: AUD 0.027
Transaction Features: Subsequent Direct Listing Reported Earnings • Feb 25
First half 2024 earnings released: NZ$0.031 loss per share (vs NZ$0.008 profit in 1H 2023) First half 2024 results: NZ$0.031 loss per share (down from NZ$0.008 profit in 1H 2023). Revenue: NZ$650.4k (down 65% from 1H 2023). Net loss: NZ$5.93m (down NZ$7.30m from profit in 1H 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance. Announcement • Feb 14
Zoono Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.054 million. Zoono Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.054 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,000,000
Price\Range: AUD 0.027
Transaction Features: Subsequent Direct Listing New Risk • Jan 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 19% per year over the past 5 years. Market cap is less than US$10m (AU$9.29m market cap, or US$6.11m). Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Revenue is less than US$5m (NZ$3.3m revenue, or US$2.0m). Announcement • Oct 06
Zoono Group Limited, Annual General Meeting, Nov 27, 2023 Zoono Group Limited, Annual General Meeting, Nov 27, 2023, at 11:01 AUS Eastern Standard Time. Reported Earnings • Aug 25
Full year 2023 earnings released: NZ$0.002 loss per share (vs NZ$0.069 loss in FY 2022) Full year 2023 results: NZ$0.002 loss per share (improved from NZ$0.069 loss in FY 2022). Revenue: NZ$3.34m (down 63% from FY 2022). Net loss: NZ$350.4k (loss narrowed 97% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance. New Risk • Jul 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 8.4% per year over the past 5 years. Market cap is less than US$10m (AU$9.69m market cap, or US$6.52m). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Revenue is less than US$5m (NZ$4.8m revenue, or US$3.0m). Reported Earnings • Feb 24
First half 2023 earnings released: EPS: NZ$0.008 (vs NZ$0.012 loss in 1H 2022) First half 2023 results: EPS: NZ$0.008 (up from NZ$0.012 loss in 1H 2022). Revenue: NZ$1.85m (down 70% from 1H 2022). Net income: NZ$1.37m (up NZ$3.36m from 1H 2022). Profit margin: 74% (up from net loss in 1H 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 19 percentage points per year, which is a significant difference in performance. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Non-Executive Independent Director Don Clarke was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Oct 25
Zoono Group Limited, Annual General Meeting, Nov 25, 2022 Zoono Group Limited, Annual General Meeting, Nov 25, 2022, at 10:00 AUS Eastern Standard Time. Location: Conference Room 1, Hall Chadwick Level 40, 2 Park Street Sydney Australia Agenda: To Adopt the Remuneration Report; to consider Election of Mr. Don Clarke; to consider Approval of Issue of Securities under an Employee Incentive Plan; to consider Approval for Additional Share Placement Capacity. Announcement • Oct 17
Zoono Group Limited Develops New Nasal Spray Product Zoono Group Limited announced the development of the first of its specialty products for use in the clinical, medical and OTC sectors. Over the past 18 months, Zoono has been working closely with the Faculty of Medical and Health Sciences at the University of Auckland, examining the effects of Zoono technology on staphylococcus and pseudomonas biofilms in the laboratory. These pathogens are often detected in patients experiencing sinusitis and can be very resistant to treatment with antibiotics. Chronic rhinosinusitis is a common condition that causes a marked reduction in quality of life for those who suffer from it. This project has been partially funded by a grant from the New Zealand Government Science and Innovation Agency. The University team has been led by Professor Richard Douglas - a specialist ORL surgeon with clinical and research interests in the medical and surgical management of chronic rhinosinusitis. He is a consultant surgeon at Auckland City and Gillies Hospitals and is a Professor of Surgery at the University of Auckland. His project team includes Dr. Brett Wagner-MacKenzie, a research fellow in the Department of Surgery at the University of Auckland. The test results from the product trials completed at the University have exceeded all expectations. The testing confirmed: a significant reduction in viable staphylococcus aureus biofilms at one hour and eradication at six hours; and a significant reduction in viable pseudomonas aeruginosa biofilms at 5 minutes and near eradication within one 1 hour. The new formulation will be sold as a treatment of chronic rhinosinusitis (CRS) - a condition that is estimated to affect 12.3% of the population in the USA, 10.9% in Europe and 13% in China. Zoono is keen to expand its product range into this market as the global inhalation and nasal spray generic drugs market was estimated at USD 17.50 billion in 2021. Further, it is expected to expand at a compound annual growth rate of circa 9% from 2022 to 2030. Another material advantage of the new Zoono product is that it has the potential to substantially reduce the use of antibiotics in the treatment of sinusitis, thereby reducing the potential for the development of antibiotic resistance. The Zoono technology does not promote mutation and pathogens are unable to develop immunity. Reported Earnings • Aug 26
Full year 2022 earnings released: NZ$6.82 loss per share (vs NZ$0.029 profit in FY 2021) Full year 2022 results: NZ$6.82 loss per share (down from NZ$0.029 profit in FY 2021). Revenue: NZ$9.02m (down 67% from FY 2021). Net loss: NZ$11.4m (down 341% from profit in FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 208 percentage points per year, which is a significant difference in performance. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Non-Executive Independent Director Don Clarke was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 02
Zoono Group Limited Appoints Barry Woolcott as Group Chief Executive Officer ZOONO Group Limited advised the appointment of Mr. Barry Woolcott as Group Chief Executive Officer (CEO). Following an extensive executive search, Mr. Woolcott joined Zoono in September 2021, initially as Global General Manager, with the intention that, at a mutually agreed date, he would assume the role of Chief Executive Officer. Prior to joining Zoono, Mr. Woolcott developed his management capabilities through 7 years at Deloitte and, more recently, 13 years (the last 8 as Group CEO) at Jacobsen Holdings. Importantly for Zoono, Mr. Paul Hyslop will continue to be actively engaged in the business, both as an executive with an emphasis on major customers and new projects and as an on-going member of the Board. Buying Opportunity • Jan 24
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be NZ$0.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 92% per annum over the last 3 years. Earnings per share has grown by 91% per annum over the last 3 years. Reported Earnings • Aug 27
Full year 2021 earnings released: EPS NZ$0.029 (vs NZ$0.10 in FY 2020) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: NZ$27.1m (down 29% from FY 2020). Net income: NZ$4.73m (down 72% from FY 2020). Profit margin: 17% (down from 44% in FY 2020). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 91% per year whereas the company’s share price has increased by 89% per year. Recent Insider Transactions • Jun 12
CEO, MD & Director recently sold AU$4.9m worth of stock On the 3rd of June, Paul Hyslop sold around 7m shares on-market at roughly AU$0.70 per share. This was the largest sale by an insider in the last 3 months. This was Paul's only on-market trade for the last 12 months. Announcement • Jun 09
STERLING INVESTMENT MANAGEMENT and Regal Funds Management Pty Limited acquired 4.% stake in Zoono Group Limited (ASX:ZNO) for AUD 4.9 million. STERLING INVESTMENT MANAGEMENT and Regal Funds Management Pty Limited acquired 4.% stake in Zoono Group Limited (ASX:ZNO) for AUD 4.9 million on June 8, 2021. STERLING INVESTMENT MANAGEMENT and Regal Funds Management Pty Limited will acquire 2 million and 5 million shares at AUD of 0.7 per share.
STERLING INVESTMENT MANAGEMENT and Regal Funds Management Pty Limited acquired 4.% stake in Zoono Group Limited (ASX:ZNO) on June 8, 2021. Valuation Update With 7 Day Price Move • Apr 27
Investor sentiment improved over the past week After last week's 31% share price gain to NZ$1.06, the stock trades at a trailing P/E ratio of 9.6x. Average trailing P/E is 33x in the Chemicals industry in Australia. Total returns to shareholders of 549% over the past three years. Reported Earnings • Mar 02
First half 2021 earnings released: EPS NZ$0.012 (vs NZ$0.004 loss in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: NZ$14.4m (up NZ$12.7m from 1H 2020). Net income: NZ$1.91m (up NZ$2.63m from 1H 2020). Profit margin: 13% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 27
New 90-day low: AU$0.67 The company is down 52% from its price of AU$1.39 on 27 November 2020. The Australian market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is down 8.0% over the same period. Announcement • Feb 19
Zoono Group Limited to Report First Half, 2021 Results on Feb 25, 2021 Zoono Group Limited announced that they will report first half, 2021 results on Feb 25, 2021 Is New 90 Day High Low • Feb 10
New 90-day low: AU$0.94 The company is down 32% from its price of AU$1.38 on 12 November 2020. The Australian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 9.0% over the same period. Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment deteriorated over the past week After last week's 19% share price decline to NZ$1.04, the stock is trading at a trailing P/E ratio of 10.9x, down from the previous P/E ratio of 13.4x. This compares to an average P/E of 36x in the Chemicals industry in Australia. Total returns to shareholders over the past three years are 197%. Is New 90 Day High Low • Jan 18
New 90-day low: AU$1.27 The company is down 14% from its price of AU$1.47 on 20 October 2020. The Australian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is flat over the same period. Is New 90 Day High Low • Dec 11
New 90-day low: AU$1.31 The company is down 39% from its price of AU$2.16 on 11 September 2020. The Australian market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 1.0% over the same period. Valuation Update With 7 Day Price Move • Nov 03
Market bids up stock over the past week After last week's 20% share price gain to NZ$1.58, the stock is trading at a trailing P/E ratio of 16.5x, up from the previous P/E ratio of 13.8x. This compares to an average P/E of 18x in the Chemicals industry in Australia. Total returns to shareholders over the past three years are 269%. Valuation Update With 7 Day Price Move • Oct 16
Market pulls back on stock over the past week After last week's 22% share price decline to NZ$1.44, the stock is trading at a trailing P/E ratio of 15.1x, down from the previous P/E ratio of 19.3x. This compares to an average P/E of 19x in the Chemicals industry in Australia. Total returns to shareholders over the past three years are 197%. Is New 90 Day High Low • Oct 15
New 90-day low: AU$1.55 The company is down 35% from its price of AU$2.38 on 17 July 2020. The Australian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 1.0% over the same period. Is New 90 Day High Low • Sep 29
New 90-day low: AU$1.79 The company is down 37% from its price of AU$2.82 on 01 July 2020. The Australian market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 2.0% over the same period. Announcement • Sep 22
Zoono Group Limited Provides Updates on Legal Disputes Zoono Group Limited provided updates on legal disputes. Zoono takes a strong line on its Distribution Agreements. Its policy is that distributors must meet minimum sales obligations (as set out in their respective agreements) and, if they are unable to do so, face termination for non- performance. As a result of this policy, Zoono is now involved in two disputes involving legal proceedings in New Zealand. Zoono is in dispute with China based Qingdao Zoono Biotechnology Company Limited (QZB) in relation to the termination of its Distribution Agreement. Zoono does not believe there is any merit in QZB's claim. Currently, as QZB has failed to make payments ordered by the NZ Courts, its application is stayed until such payments are made. If non-payment continues, Zoono will apply to have the claim dismissed. The second dispute relates to Zoono's termination of its Distribution Agreement with UAE based Sky Scrapers General Trading LLC (SSGT). Zoono has been advised by SSGT that it intends to initiate court proceedings seeking to have the Distribution Agreement reinstated. If it does so, Zoono intends to file a counter claim for damages for breach of that agreement. Zoono is also confident of success in this dispute. While it is unfortunate that Zoono is involved in these disputes, nothing will deter Zoono from taking what it regards as reasonable and appropriate steps to protect its business interests. Announcement • Sep 17
United Airlines Adds Zoono Group Limited's Antimicrobial Spray to Already Extensive Cabin-Cleaning Measures United Airlines announced that it is adding Zoono Microbe Shield, an EPA registered antimicrobial coating that forms a long-lasting bond with surfaces and inhibits the growth of microbes, to the airline's already rigorous safety and cleaning procedures. United is currently applying the coating each week on more than 30 aircraft to seats, tray tables, armrests, overhead bins, lavatories and crew stations and expects to add this latest measure to its entire mainline and express fleet before the end of the year. The antimicrobial coating, created by Zoono Group Limited will serve as an added layer of protection that complements the airline's existing, daily electrostatic spraying regimen before departing flights. The Zoono Microbe Shield works by bonding to surfaces and creating a protective layer that resembles microscopic pins once dry which rupture cell walls and membranes when microbes come in contact with them. The chemical is classified by the EPA as Category IV, which is the lowest level of toxicity. During an aircraft's deep cleanings, United will use the NovaRover which is designed to apply a super fine mist of the antimicrobial that coats all surfaces in a 12-foot radius with a single spray. United will apply the antimicrobial to aircraft overnight every seven days using electrostatic sprayers to refresh and fortify the protective layer, while continuing to electrostatic spray disinfectant to the aircraft cabin before almost every departure. United is currently applying Zoono Microbe Shield on aircraft at Chicago O'Hare International Airport and expects to expand it to each of its six other hubs and approximately 200 U.S. airports where United aircraft remain overnight in the coming months. The airline plans to deploy NovaRovers at ten airports, including each of United's seven hubs as well as Boston, Cleveland and Las Vegas. Announcement • Aug 12
Zoono Group Limited to Report Fiscal Year 2020 Results on Aug 20, 2020 Zoono Group Limited announced that they will report fiscal year 2020 results at 6:00 AM, GMT Standard Time on Aug 20, 2020